263 related articles for article (PubMed ID: 9836380)
1. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
Yoshizaki K; Nishimoto N; Mihara M; Kishimoto T
Springer Semin Immunopathol; 1998; 20(1-2):247-59. PubMed ID: 9836380
[No Abstract] [Full Text] [Related]
2. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
4. [A humanized anti-IL-6 receptor antibody(MRA) in RA therapy].
Hagihara K; Nishimoto N; Yoshizaki K
Nihon Rinsho; 2002 Dec; 60(12):2401-7. PubMed ID: 12510369
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD4 monoclonal antibodies in rheumatoid arthritis.
Choy EH; Kingsley GH; Panayi GS
Springer Semin Immunopathol; 1998; 20(1-2):261-73. PubMed ID: 9836381
[No Abstract] [Full Text] [Related]
7. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
[TBL] [Abstract][Full Text] [Related]
9. The blockade of IL-6 signaling in rational drug design.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
[TBL] [Abstract][Full Text] [Related]
10. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis.
Nakamura I; Omata Y; Naito M; Ito K
J Rheumatol; 2009 Feb; 36(2):459-60. PubMed ID: 19208585
[No Abstract] [Full Text] [Related]
11. [IL-6 blockade].
Kaneko Y; Takeuchi T
Nihon Rinsho; 2016 Jun; 74(6):963-7. PubMed ID: 27311186
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis.
Davies R; Choy E
Semin Immunol; 2014 Feb; 26(1):97-104. PubMed ID: 24389239
[TBL] [Abstract][Full Text] [Related]
13. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
14. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
16. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis.
Takagi N; Mihara M; Moriya Y; Nishimoto N; Yoshizaki K; Kishimoto T; Takeda Y; Ohsugi Y
Arthritis Rheum; 1998 Dec; 41(12):2117-21. PubMed ID: 9870868
[TBL] [Abstract][Full Text] [Related]
17. IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor.
Imazeki I; Saito H; Hasegawa M; Shinkura H; Kishimoto T; Ohsugi Y
Int J Immunopharmacol; 1998 Jul; 20(7):345-57. PubMed ID: 9756130
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
Cronstein BN
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
Park JY; Pillinger MH
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]